Skip to content

Study · Animal study (in vivo) · mouse · 2021

10 results

Short-term glucocorticoid excess blunts abaloparatide-induced increase in femoral bone mass and strength in mice.

Brent MB, Thomsen JS, Brüel A

Scientific reports10 Jun 2021Cited by 13 (Europe PMC)

PMID34112892 (opens in a new tab)PMCIDPMC8192916 (opens in a new tab)DOI10.1038/s41598-021-91729-8 (opens in a new tab)PepBankPUB-34112892
Download PDFPubMedAsk about this study
Jump to 10 results

Summary

Glucocorticoids (GCs), such as prednisolone, are widely used to treat inflammatory diseases. Continuously long-term or high dose treatment with GCs is one of the most common causes of secondary osteoporosis and is associated with sarcopenia and increased risk of debilitating osteoporotic fragility fractures. Abaloparatide (ABL) is a potent parathyroid hormone-related peptide analog, which can increase bone mineral density (aBMD), improve trabecular microarchitecture, and increase bone strength. The present study aimed to investigate whether GC excess blunts the osteoanabolic effect of ABL. Sixty 12-13-week-old female RjOrl:SWISS mice were allocated to the following groups: Baseline, Control, ABL, GC, and GC + ABL. ABL was administered as subcutaneous injections (100 μg/kg), while GC was delivered by subcutaneous implantation of a 60-days slow-release prednisolone-pellet (10 mg). The study lasted four weeks. GC induced a substantial reduction in muscle mass, trabecular mineral apposition rate (MAR) and bone formation rate (BFR/BS), and endocortical MAR compared with Control, but did not alter the trabecular microarchitecture or bone strength. In mice not receiving GC, ABL increased aBMD, bone mineral content (BMC), cortical and trabecular microarchitecture, mineralizing surface (MS/BS), MAR, BFR/BS, and bone strength compared with Control. However, when administered concomitantly with GC, the osteoanabolic effect of ABL on BMC, cortical morphology, and cortical bone strength was blunted. In conclusion, at cortical bone sites, the osteoanabolic effect of ABL is generally blunted by short-term GC excess.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study10

7 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice without glucocorticoid exposure, abaloparatide increased areal BMD versus control.

    In plain wordsIn mice without glucocorticoid exposure, abaloparatide increased bone density versus control.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseAreal BMD
    Study

    mousen: not reported in source

    Female RjOrl:SWISS mice
    Comparator
    Control without glucocorticoid
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 μg/kg · subcutaneous · four weeksAs given in this study (mouse).

    Source sentences

    Summary
    In mice not receiving GC, ABL increased aBMD, bone mineral content (BMC), cortical and trabecular microarchitecture, mineralizing surface (MS/BS), MAR, BFR/BS, and bone strength compared with Control.
    3 context sentences
    Summary · context
    Sixty 12-13-week-old female RjOrl:SWISS mice were allocated to the following groups: Baseline, Control, ABL, GC, and GC + ABL.
    Summary · context
    ABL was administered as subcutaneous injections (100 μg/kg), while GC was delivered by subcutaneous implantation of a 60-days slow-release prednisolone-pellet (10 mg).
    Summary · context
    The study lasted four weeks.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice without glucocorticoid exposure, abaloparatide increased bone mineral content versus control.

    In plain wordsIn mice without glucocorticoid exposure, abaloparatide increased bone mineral content versus control.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseBone mineral content
    Study

    mousen: not reported in source

    Female RjOrl:SWISS mice
    Comparator
    Control without glucocorticoid
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 μg/kg · subcutaneous · four weeksAs given in this study (mouse).

    Source sentences

    Summary
    In mice not receiving GC, ABL increased aBMD, bone mineral content (BMC), cortical and trabecular microarchitecture, mineralizing surface (MS/BS), MAR, BFR/BS, and bone strength compared with Control.
    3 context sentences
    Summary · context
    Sixty 12-13-week-old female RjOrl:SWISS mice were allocated to the following groups: Baseline, Control, ABL, GC, and GC + ABL.
    Summary · context
    ABL was administered as subcutaneous injections (100 μg/kg), while GC was delivered by subcutaneous implantation of a 60-days slow-release prednisolone-pellet (10 mg).
    Summary · context
    The study lasted four weeks.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In mice without glucocorticoid exposure, abaloparatide improved cortical and trabecular microarchitecture versus control.

    In plain wordsIn mice without glucocorticoid exposure, abaloparatide improved cortical and trabecular bone structure versus control.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseCortical and trabecular microarchitecture
    Study

    mousen: not reported in source

    Female RjOrl:SWISS mice
    Comparator
    Control without glucocorticoid
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 μg/kg · subcutaneous · four weeksAs given in this study (mouse).

    Source sentences

    Summary
    In mice not receiving GC, ABL increased aBMD, bone mineral content (BMC), cortical and trabecular microarchitecture, mineralizing surface (MS/BS), MAR, BFR/BS, and bone strength compared with Control.
    3 context sentences
    Summary · context
    Sixty 12-13-week-old female RjOrl:SWISS mice were allocated to the following groups: Baseline, Control, ABL, GC, and GC + ABL.
    Summary · context
    ABL was administered as subcutaneous injections (100 μg/kg), while GC was delivered by subcutaneous implantation of a 60-days slow-release prednisolone-pellet (10 mg).
    Summary · context
    The study lasted four weeks.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In mice without glucocorticoid exposure, abaloparatide increased mineralizing surface versus control.

    In plain wordsIn mice without glucocorticoid exposure, abaloparatide increased mineralizing surface versus control.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseMineralizing surface
    Study

    mousen: not reported in source

    Female RjOrl:SWISS mice
    Comparator
    Control without glucocorticoid
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 μg/kg · subcutaneous · four weeksAs given in this study (mouse).

    Source sentences

    Summary
    In mice not receiving GC, ABL increased aBMD, bone mineral content (BMC), cortical and trabecular microarchitecture, mineralizing surface (MS/BS), MAR, BFR/BS, and bone strength compared with Control.
    3 context sentences
    Summary · context
    Sixty 12-13-week-old female RjOrl:SWISS mice were allocated to the following groups: Baseline, Control, ABL, GC, and GC + ABL.
    Summary · context
    ABL was administered as subcutaneous injections (100 μg/kg), while GC was delivered by subcutaneous implantation of a 60-days slow-release prednisolone-pellet (10 mg).
    Summary · context
    The study lasted four weeks.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In mice without glucocorticoid exposure, abaloparatide increased mineral apposition rate versus control.

    In plain wordsIn mice without glucocorticoid exposure, abaloparatide increased mineral apposition rate versus control.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseMineral apposition rate
    Study

    mousen: not reported in source

    Female RjOrl:SWISS mice
    Comparator
    Control without glucocorticoid
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 μg/kg · subcutaneous · four weeksAs given in this study (mouse).

    Source sentences

    Summary
    In mice not receiving GC, ABL increased aBMD, bone mineral content (BMC), cortical and trabecular microarchitecture, mineralizing surface (MS/BS), MAR, BFR/BS, and bone strength compared with Control.
    3 context sentences
    Summary · context
    Sixty 12-13-week-old female RjOrl:SWISS mice were allocated to the following groups: Baseline, Control, ABL, GC, and GC + ABL.
    Summary · context
    ABL was administered as subcutaneous injections (100 μg/kg), while GC was delivered by subcutaneous implantation of a 60-days slow-release prednisolone-pellet (10 mg).
    Summary · context
    The study lasted four weeks.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In mice without glucocorticoid exposure, abaloparatide increased bone formation rate versus control.

    In plain wordsIn mice without glucocorticoid exposure, abaloparatide increased bone formation rate versus control.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseBone formation rate
    Study

    mousen: not reported in source

    Female RjOrl:SWISS mice
    Comparator
    Control without glucocorticoid
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 μg/kg · subcutaneous · four weeksAs given in this study (mouse).

    Source sentences

    Summary
    In mice not receiving GC, ABL increased aBMD, bone mineral content (BMC), cortical and trabecular microarchitecture, mineralizing surface (MS/BS), MAR, BFR/BS, and bone strength compared with Control.
    3 context sentences
    Summary · context
    Sixty 12-13-week-old female RjOrl:SWISS mice were allocated to the following groups: Baseline, Control, ABL, GC, and GC + ABL.
    Summary · context
    ABL was administered as subcutaneous injections (100 μg/kg), while GC was delivered by subcutaneous implantation of a 60-days slow-release prednisolone-pellet (10 mg).
    Summary · context
    The study lasted four weeks.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In mice without glucocorticoid exposure, abaloparatide increased bone strength versus control.

    In plain wordsIn mice without glucocorticoid exposure, abaloparatide increased bone strength versus control.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseBone strength
    Study

    mousen: not reported in source

    Female RjOrl:SWISS mice
    Comparator
    Control without glucocorticoid
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 μg/kg · subcutaneous · four weeksAs given in this study (mouse).

    Source sentences

    Summary
    In mice not receiving GC, ABL increased aBMD, bone mineral content (BMC), cortical and trabecular microarchitecture, mineralizing surface (MS/BS), MAR, BFR/BS, and bone strength compared with Control.
    3 context sentences
    Summary · context
    Sixty 12-13-week-old female RjOrl:SWISS mice were allocated to the following groups: Baseline, Control, ABL, GC, and GC + ABL.
    Summary · context
    ABL was administered as subcutaneous injections (100 μg/kg), while GC was delivered by subcutaneous implantation of a 60-days slow-release prednisolone-pellet (10 mg).
    Summary · context
    The study lasted four weeks.

Studies that did not test the peptide alone3

In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Abaloparatide (Tymlos).

  1. 08AnimalNot a test of Abaloparatide (Tymlos) aloneAnimal study (in vivo)Efficacy outcome

    In mice, concomitant glucocorticoid exposure blunted the abaloparatide-associated increase in bone mineral content.

    In plain wordsIn mice, glucocorticoid plus abaloparatide produced a smaller bone mineral content response than abaloparatide without glucocorticoid.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    DecreaseGlucocorticoid attenuation of bone mineral content response
    Study

    mousen: not reported in source

    Female RjOrl:SWISS mice
    Comparator
    Abaloparatide without glucocorticoid
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    However, when administered concomitantly with GC, the osteoanabolic effect of ABL on BMC, cortical morphology, and cortical bone strength was blunted.
    3 context sentences
    Summary · context
    Sixty 12-13-week-old female RjOrl:SWISS mice were allocated to the following groups: Baseline, Control, ABL, GC, and GC + ABL.
    Summary · context
    ABL was administered as subcutaneous injections (100 μg/kg), while GC was delivered by subcutaneous implantation of a 60-days slow-release prednisolone-pellet (10 mg).
    Summary · context
    The study lasted four weeks.

    In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).

  2. 09AnimalNot a test of Abaloparatide (Tymlos) aloneAnimal study (in vivo)Efficacy outcome

    In mice, concomitant glucocorticoid exposure blunted the abaloparatide-associated improvement in cortical morphology.

    In plain wordsIn mice, glucocorticoid plus abaloparatide produced a smaller cortical morphology response than abaloparatide without glucocorticoid.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    DecreaseGlucocorticoid attenuation of cortical morphology response
    Study

    mousen: not reported in source

    Female RjOrl:SWISS mice
    Comparator
    Abaloparatide without glucocorticoid
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    However, when administered concomitantly with GC, the osteoanabolic effect of ABL on BMC, cortical morphology, and cortical bone strength was blunted.
    3 context sentences
    Summary · context
    Sixty 12-13-week-old female RjOrl:SWISS mice were allocated to the following groups: Baseline, Control, ABL, GC, and GC + ABL.
    Summary · context
    ABL was administered as subcutaneous injections (100 μg/kg), while GC was delivered by subcutaneous implantation of a 60-days slow-release prednisolone-pellet (10 mg).
    Summary · context
    The study lasted four weeks.

    In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).

  3. 10AnimalNot a test of Abaloparatide (Tymlos) aloneAnimal study (in vivo)Efficacy outcome

    In mice, concomitant glucocorticoid exposure blunted the abaloparatide-associated increase in cortical bone strength.

    In plain wordsIn mice, glucocorticoid plus abaloparatide produced a smaller cortical strength response than abaloparatide without glucocorticoid.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    DecreaseGlucocorticoid attenuation of cortical strength response
    Study

    mousen: not reported in source

    Female RjOrl:SWISS mice
    Comparator
    Abaloparatide without glucocorticoid
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    However, when administered concomitantly with GC, the osteoanabolic effect of ABL on BMC, cortical morphology, and cortical bone strength was blunted.
    3 context sentences
    Summary · context
    Sixty 12-13-week-old female RjOrl:SWISS mice were allocated to the following groups: Baseline, Control, ABL, GC, and GC + ABL.
    Summary · context
    ABL was administered as subcutaneous injections (100 μg/kg), while GC was delivered by subcutaneous implantation of a 60-days slow-release prednisolone-pellet (10 mg).
    Summary · context
    The study lasted four weeks.

    In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.